Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZR2 Regimen in Primary or Secondary CNS Lymphoma
NCT04938297Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2021
- Primary completion
- Oct 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zanubrutinib in primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL) (3 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Overall Response Rate. Started May 2021; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on NCT04938297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04938297.